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Objective—Our aim in this study was to provide novel information on the molecular mechanisms playing a major role in
the unwanted platelet activation associated with ST-elevation myocardial infarction (STEMI).
Methods and Results—We compared the platelet proteome of 11 STEMI patients to a matched control group of 15 stable
chronic ischemic cardiopathy patients. In addition, we did a prospective study to follow the STEMI patients over time.
Proteins were separated by high-resolution 2D gel electrophoresis, identified by mass spectrometry, and validated by
Western blotting. Platelets from STEMI patients on admission displayed 56 protein spot differences (corresponding to
42 unique genes) compared with the control group. The number of differences decreased with time during the patients’
follow-up. Interestingly, the adapter protein CrkL and the active form of Src (phosphorylated in Tyr418) were found to
be upregulated in platelets from STEMI patients. Major signaling pathways related to the proteins identified include
integrin, integrin-linked kinase, and glycoprotein VI (GPVI) signaling. Interestingly, a study on an independent cohort
of patients showed a higher degree of activation of GPVI signaling in STEMI patients.
Conclusion—CrkL, the active form of Src, and GPVI signaling are upregulated in platelets from STEMI patients. (Arterioscler
Thromb Vasc Biol. 2011;31:2957-2964.)
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Acute coronary syndromes (ACSs) encompass unstableangina, non-ST segment elevation (NSTE) myocardial
infarction, and ST-segment elevation myocardial infarction
(STEMI). The latter usually occurs when thrombus forms on
a ruptured atheromatous plaque and causes a prolonged
occlusion of an epicardial coronary artery.1 There is no doubt
platelets play a fundamental role in the pathogenesis of an
ACS, being implicated in the thrombus formation that follows
the atheroma plaque rupture.2 Activated platelets release
proteins in the coronary circulation of ACS patients, such as
matrix metalloproteinases, that contribute to sustained intra-
coronary platelet activation.3 Following an ACS, antiplatelet
therapy is recommended to reduce the growth of a thrombus.
Primary targets of such therapy are molecules involved in
platelet activation and aggregation. Nevertheless, there is a
need for the development of a new generation of safer and
more effective antithrombotic drugs with larger therapeutic
windows and for a better understanding of the pathogenic
processes that lead to thrombotic occlusion of blood vessels
linked to an acute event.2
Proteomics has emerged as a promising tool in cardiovas-
cular research, and more precisely in the study of ACSs.4
Studies have included plasma, monocytes, and, very recently,
platelets.5–8 The objective of these studies was the identification
of novel screening and diagnostic biomarkers that might help to
predict the disease and provide novel information on the molec-
ular events associated with it, hopefully leading to the identifi-
cation of novel drug targets. We have been involved in the
platelet studies and thus have recently published a high-
resolution 2D gel electrophoresis–based study of the platelet
proteome of patients with NSTE-ACS.7 We now present the first
analysis of the platelet proteome from patients with STEMI
compared with matched stable coronary artery disease (SCAD)
controls. We also did a prospective study to follow the STEMI
patients over time and a specific analysis of the collagen receptor
glycoprotein VI (GPVI) signaling cascade in an independent
cohort of patients. Our primary objective was to provide,
through a global proteomic approach, novel information on the
molecular mechanisms playing a major role in the unwanted
platelet activation associated with STEMI.
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Methods
Patients
Eleven patients admitted into a tertiary hospital in the northwest of
Spain presenting with STEMI (defined as angina pain of at least 20
minutes’ duration with elevated cardiac enzymes and ST-segment
elevation of at least 0.1 mV in 2 or more contiguous leads or
presumably new left bundle branch block) entered the study. Exclu-
sion criteria were inflammatory or neoplastic diseases; coagulation
disorders; platelet-associated disorders; other significant heart dis-
ease except left ventricular hypertrophy secondary to hypertension;
chronic drug therapy (except for drugs required to treat preexisting
clinical atherosclerosis or its risk factors); and having experienced
surgical procedures, major traumatisms, thromboembolic events, or
revascularization procedures in the previous 3 months.
The study was approved by the local Ethics Committee (Galician
Clinical Investigation Ethics Committee) and developed according to
the principles outlined in the Declaration of Helsinki. At the moment
of diagnosis, the patients were asked to participate in the study. In
case of acceptance, they signed the informed consent, and 27 mL of
blood were collected in sodium citrate BD Vacutainer tubes for
analysis. All samples were obtained within the first 12 hours
following the initiation of the symptoms, after arrival at the emer-
gency department. In most cases, patients were administered aspirin
before arrival to hospital, so aspirin-pretreated patients were admit-
ted in the study. Some patients had also clopidogrel treatment and
were also admitted. However, patients previously treated with
anti-IIb3 drugs were excluded because in this case discrimination
was easier (these drugs are administered at the hospital). When
anti-IIb3 drugs had been already administrated before blood
extraction, we decided to exclude those patients to minimize the use
of antiplatelet drugs in the study and also because it would have been
difficult to find good SCAD matched controls. A second blood
sample was taken on day 5 to investigate whether there was a fast
reversal of the changes observed in the platelet proteome on
admission. Another blood sample was taken after 6 months. Blood
was also collected from 15 matched SCAD patients experiencing
stable chronic ischemic cardiopathy. Such a group was decided to be
the most adequate control group because of the clinical characteris-
tics of the STEMI patients. SCAD patients were required not to have
a history of acute cardiovascular event within the year before the
inclusion in the study. An age- and sex-matched healthy control
group consisting of 10 volunteers was also included for validation
studies.
Platelet Isolation
Platelets were isolated by an established method that limits contam-
ination from other blood cells as described previously.9 Washed
platelets were resuspended in Tyrodes-HEPES (134 mmol/L NaCl,
0.34 mmol/L Na2HPO4, 2.9 mmol/L KCl, 12 mmol/L NaHCO3,
20 mmol/L HEPES, 5 mmol/L glucose, 1 mmol/L MgCl2, pH 7.3) at
6108 platelets/mL and allowed to rest for 30 minutes at room
temperature. Platelets were then spun down at 10 000 g in the
presence of 1 mmol/L EGTA and, after addition of 5 L of a
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), imme-
diately frozen in liquid nitrogen for a few seconds followed by the
addition of 2D gel electrophoresis sample buffer (see below). Protein
samples were stored at 80°C.
For GPVI signaling studies, 500-L aliquots of platelets (6108/
mL) were warmed at 37°C for 10 minutes in the presence of
1 mmol/L EGTA, 10 mol/L indomethacin, and 2 U/mL apyrase
before stimulation for 90 seconds with collagen-related peptide
(CRP) (final concentration of 10 g/mL). Stimulations were with
constant stirring at 1200 rpm in a Chrono-log aggregometer. Un-
stimulated (basal) samples were processed in parallel but treated with
CRP diluent (0.01 mol/L acetic acid containing 0.1% fatty acid–free
BSA) alone. Basal and stimulated platelets were lysed for Western
blot analysis as described previously.10
Proteomic Analysis
Protein quantitation was done with the Coomassie Plus protein
reagent (Thermo Scientific, Asheville, NC). Six hundred micrograms
of protein were loaded onto each gel to allow detection of low
abundant proteins. An individual gel was run for each blood sample,
from each STEMI patient, at 3 different times: on admission, after 5
days, and after 6 months. One sample was obtained from each SCAD
patient. The remaining protein was used for Western blotting.
For each sample, protein was dissolved in 500 L of 2D sample
buffer (5 mol/L urea, 2 mol/L thiourea, 2 mmol/L tributylphosphine,
65 mmol/L dithiothreitol, 65 mmol/L CHAPS, 0.15 mol/L NDSB-
256, 1 mmol/L sodium vanadate, 0.1 mmol/L sodium fluoride, and
1 mmol/L benzamidine). Ampholytes (Servalyte 4-7) were added to
the sample to a final concentration of 1.6% (v/v). The first dimension
was on immobilized pH gradient strips 4 to 7, 24 cm (GE Health-
care). The second dimension was by SDS-polyacrylamide gel
electrophoresis (PAGE) on 10% gels. Protein staining was with
Sypro Ruby fluorescent dye. Differential image analysis was with
Ludesi REDFIN 3 software (Lund, Sweden). Further information
on the 2D gel electrophoresis protocol and image analysis can be
found in the Supplemental Methods, available online at
http://atvb.ahajournals.org.
Protein features chosen for mass spectrometric analyses were
excised from the gels and in-gel digested with trypsin. Proteins were
identified using a 4800 matrix-assisted laser desorption ionization/
tandem time of flight analyzer (Applied Biosystems) and a Bruker
Amazon electron transfer dissociation ion trap. A database search
was performed with the Mascot v2.1 search tool (Matrix Science,
London, United Kingdom) screening SwissProt (release 56.0). Fur-
ther details on the analysis can be found in the Supplemental
Methods.
Western Blotting
Western blot analyses were carried out on polyvinylidene difluoride
membranes using the following primary antibodies and dilutions:
rabbit anti-CrkL (1:500) from Santa Cruz Biotechnology, Inc (Santa
Cruz, CA), rabbit anti-Src (pTyr418) (1:1000) from Invitrogen
(Camarillo, CA), mouse anti-phosphotyrosine monoclonal antibody
(clone 4G10) (1:1000) from Millipore (Billerica, MA), and mouse
anti-GAPDH (0.5 g/mL) from Ambion (Austin, TX). Membranes
were exposed to horseradish peroxidase–labeled goat anti-rabbit or
goat anti-mouse antibodies (dilution 1:5000) (Pierce, Rockford, IL),
processed using an enhanced chemiluminescence system (ECL,
Pierce), and quantified by densitometry. Further details on the
Western blot protocol can be found in the Supplemental Methods.
Ingenuity Pathways Analysis
Ingenuity Pathways Analysis software (Ingenuity Systems) was used
to investigate possible interactions between all the identified pro-
teins. Interactive pathways were generated to observe potential direct
and indirect relations among the differentially expressed proteins.
Statistical Analysis
Data for categorical or dichotomous variables are expressed as
percentages and were compared using the 2 test or the Fisher exact
test. Unless stated otherwise, data for continuous variables are
expressed as the median and interquartile range and were compared
by Mann-Whitney test. The differential proteomic analysis was done
analyzing all the spots between patients with STEMI and SCAD; for
a given spot, the probability value was calculated using the quanti-
fied and normalized volumes for the matched spot in each of the
images and applying the Mann-Whitney test.
All probability values were 2-tailed, and values of 0.05 were
considered to indicate statistical significance. All analyses were




Eleven patients admitted to hospital with the diagnosis of
STEMI and 15 age and gender-matched patients with SCAD
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were included in the proteomic study. The matching was also
based on antiplatelet treatment performed before blood ex-
traction. There were only a few clinical differences between
both groups, as shown in Table 1 and Supplemental Table I.
Patients included in the SCAD control group had a higher
prevalence of 1-vessel coronary disease, whereas in STEMI
patients, complex, multivessel lesions were more frequent.
Prehospital admission use of angiotensin-converting enzyme
inhibitors and statins was more prevalent in the SCAD group.
Finally, regarding laboratory results, patients with acute
events presented higher leukocyte and glucose levels and
lower protein and mean platelet volume compared with stable
patients.
Platelet Proteome Analysis of STEMI Patients
A mean (SD) of 242653 protein features were found on pI
4 to 7 gels corresponding to platelets from SCAD patients,
whereas 246656 protein features were found in the STEMI
samples. We focused on the identification of disappearing
and appearing spots, as well as up- and downregulation of
spot intensities where the fold change was at least 1.5 (with
P0.05). By applying these criteria, 56 protein features were
detected as differentially regulated when comparing the
platelet proteome of STEMI patients on admission versus
SCAD controls (Figure 1). All protein features were success-
fully identified by mass spectrometry. They corresponded to
42 different open reading frames (Supplemental Tables II and
III). Forty of the protein features identified were upregulated
in STEMI samples gels, whereas 16 were downregulated.
Eight proteins were represented in the gels by more than 1
spot, and 8 spots had more than 1 protein, normally from the
same family.
The number of proteins differentially regulated in platelets
from STEMI patients, as compared with stable controls, was
decreasing with time. As mentioned above, on admission
there were 56 differentially regulated protein features. Of
those 56, only 32 remained significantly different at day 5.
After 6 months, only 4 protein spots remained significantly
different (Supplemental Table IV).
The 42 differentially regulated proteins identified in the
STEMI study can be divided in the following functional
groups: cytoskeletal (38%), signaling (24%), extracellular/
vesicles/secretory trafficking pathway (21%), and other
(17%). A close-up view of a selection of differentially
regulated proteins is shown in Figure 2.
A selection of proteins was validated by Western blotting.
Below, we present data on signaling proteins.
Table 1. Clinical Characteristics of ST-Elevation Myocardial









Age, y 69 (50–79) 67 (47–73)











Platelets/L 268 000 (178 000–303 000) 223000 (199 000–239 500)
Treatments
Aspirin, % 90.9 100.0




Anticoagulants, % 0 0
Data are presented as the median and interquartile range or percentage of
patients. Further information can be found in Supplemental Table I. Hx indicates
medical history.
*P0.05.
Figure 1. High-resolution 2D gel electrophoresis–based pro-
teome analysis of platelets from ST-segment elevation myocar-
dial infarction (STEMI) patients. Shown are representative 2D gel
electrophoresis gel images of STEMI and stable coronary artery
disease (SCAD) circulating platelets (isoelectric focusing: pH
range 4–7; second dimension: 10% SDS-PAGE). The figure
shows the location on the 2D gels of those spots differentially
regulated when comparing STEMI patients and SCAD controls.
Protein identifications are shown by the identification numbers
in Supplemental Table II. Further information can be found in
Supplemental Table III.
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Active Src (pTyr418) Is Upregulated in Platelets
From STEMI Patients
Our proteomic analysis revealed 1 spot corresponding to Src
downregulated in platelets from STEMI patients (Figure 2A).
Src is a 60-kDa nonreceptor tyrosine kinase involved in
initiating signaling from various tyrosine kinase-linked plate-
let receptors.11 Src and other members of the Src kinase
family are tightly regulated by tyrosine phosphorylation, so
we hypothesized that the difference we were observing could
be due to Src phosphorylation/dephosphorylation. Full cata-
lytic activity of Src requires phosphorylation of tyrosine 418,
which is located in the catalytic domain. By using a specific
anti-Src (pTyr418) antibody, we demonstrated that the active
form of Src was upregulated in platelets from STEMI patients
(Figure 3). This apparent contradiction with the proteomic
results is not actually a contradiction: when there is an
increase in phosphorylation of a given protein, spots corre-
sponding to hypophosphorylated forms may diminish in
intensity, whereas the intensity of spots corresponding to
hyperphosphorylated forms, in a more acidic region, goes up.
In our case, we did not detect the latter. Some possible
reasons for that are that spots of interest were hidden by other
surrounding spots in the stained gel (corresponding to more
abundant proteins) or they were detected but the difference
was below the 1.5-fold change cutoff level. We should also
bear in mind that Western blotting is much more sensitive
than gel staining.
The Adapter Protein CrkL Is Upregulated in
Platelets From STEMI Patients
CrkL is a GPVI signaling protein that serves as an adapter for
Syk tyrosine kinase.12 We found this protein in 1 spot
upregulated in platelets from STEMI patients (see Figure 2C).
Validation studies confirmed this result (Figure 3).
Ingenuity Pathways Analysis
Ingenuity Pathways Analysis software (Ingenuity Systems)
was used to investigate possible interactions between all the
identified proteins to highlight predominant networks and
pathways. Interestingly, 35 of the 42 differentially regulated
proteins identified are interconnected as a part of a common
network related to tissue and cell morphology (Supplemental
Figure I). The top molecular and cellular functions are
cell-to-cell signaling and interaction, cellular assembly and
organization, and cell morphology (Supplemental Figure
IIA). The top 3 canonical pathways related to the proteins
identified are actin cytoskeleton signaling, integrin signaling,
and integrin-linked kinase signaling (Supplemental Figure
IIB). In addition, 7 differentially regulated proteins are also
known to be involved in platelet activation by the collagen
receptor GPVI: -actinin-1, Src, SKAP-55 homologue,
Gads,13 SH2 domain-containing tyrosine phosphatase-1,14
Figure 2. Selection of proteins differentially regulated between
ST-segment elevation myocardial infarction (STEMI) and stable
coronary artery disease (SCAD) patients. Enlargement of repre-
sentative spots for Src (spot no. 1835) (A), thrombospondin-1
(spot no. 119) (B), CrkL (spot no. 1642) (C), myosin-9 (spot no.
1918) (D), and SH2 domain-containing tyrosine phosphatase-1
(spot no. 1723) (E). Left (i), representative 2D gel electrophoresis
images. Right (ii), bar graph for each spot showing variations in
mean volumeSD in different groups: SCAD (n15), and STEMI
(n11). *Group of patients with higher expression of the indi-
cated protein.
Figure 3. The active form of Src (pTyr418) and CrkL are upregu-
lated in platelets from ST-segment elevation myocardial infarc-
tion (STEMI) patients. A, Western blot analysis of Src-pTyr418,
CrkL, and GAPDH protein expression levels in platelets from
STEMI patients and stable coronary artery disease (SCAD) and
healthy controls. Images are representative of the results
obtained. B, Densitometry graph representing the mean
valuesSD of band intensities corresponding to Src-pTyr418
and CrkL expression assessed by Western blot, with respect to
GAPDH, for all the patients included in the study. Statistically
significant differences are highlighted. **P0.01; *P0.05. IB
indicates immunoblot.
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Cdc42,15 and CrkL.12 A selection of differentially regulated
proteins related to platelet signaling is shown in Table 2.
GPVI Signaling Is Upregulated in STEMI Patients
As mentioned above, our data suggest the involvement of
GPVI signaling in the acute event. To further explore this
issue mechanistically, we recruited an independent cohort of
patients to investigate the activation state of the GPVI
signaling cascade. The clinical characteristics of the patients
(Supplemental Table V) were similar to those of the original
study. Platelets from 6 STEMI patients, 6 matched SCAD
controls, and 6 sex- and age-matched healthy controls were in
vitro activated with the GPVI specific agonist CRP in the
presence of EGTA (which prevents platelet aggregation
during GPVI activation) and inhibitors of secondary media-
tors (ADP, thromboxanes). Those inhibitors were used to
make sure changes in the proteome were specifically due to
GPVI signaling.13 A comparison between basal (unactivated)
and CRP-activated platelets was carried out for the 3 groups
of patients (STEMI, SCAD, healthy). To do so, equal
amounts of protein from each patient belonging to the same
group were pooled for each study point (basal, CRP) and
loaded in a 4% to 12% gradient Bis-Tris gel. Because GPVI
signaling goes primarily through tyrosine phosphorylation, a
Western blot was carried out with the 4G10 antiphosphoty-
rosine antibody. As expected, there was an increase in
tyrosine phosphorylation when platelets were activated with
CRP, but interestingly, such increase was higher in STEMI
patients (Figure 4). Moreover, because Src family kinases
play a fundamental role in GPVI signaling, we reprobed the
membranes with the anti-Src (pTyr418) antibody, which
recognizes the active form of the kinase. As can be seen in
Figure 4, CRP stimulation induced an 2-fold augment in
Src-pTyr418 levels. Interestingly, there was also an increase
in Src-pTyr418 levels in platelets from STEMI patients
compared with controls, both in basal and CRP-activated
platelets. This confirms the data from our proteomic study
and shows a higher activation of GPVI signaling in platelets
from STEMI patients. Further research is under way to study
in detail by proteomics the GPVI signaling cascade in a
bigger group of patients to identify those proteins that
contribute more importantly to the differences observed.
Discussion
The present study constitutes the first proteomic analysis of
platelets from STEMI patients, and it complements our recent
study on NSTE-ACS patients.7 The 2 analyses were done
separately because of the clinical characteristics of each
group of patients, so the SCAD control groups were different.
The results presented here provide novel information on the
molecular events related to the unwanted platelet activation
that takes place in STEMI, identifying the main pathways
involved, and confirming a higher activation of the GPVI
signaling cascade in platelets from STEMI patients.
The study design is in agreement with recent platelet
proteomic and transcriptomic studies on ACS.7,16,17 We
selected patients with SCAD as a control group to focus on
differences linked to atherothrombotic events, bypassing the
influence of antiplatelet drugs. Nevertheless, a healthy con-
trol group was included during the validation stage, as done in
the transcriptomic studies mentioned above. No significant
differences were observed between SCAD and healthy
groups in the validation studies. Study limitations are men-
tioned in the discussion section shown in the supplemental
material.
Regarding the clinical characteristics of the patients, there
was an obvious dissimilarity in treatment of the two study
groups, with SCAD patients having more frequent preadmis-
sion prescription of angiotensin-converting enzyme inhibitors
and statins because this group presented an already estab-
lished diagnosis of ischemic heart disease, compared with
patients with acute events, in whom this diagnosis was mostly
performed for the first time. Additional discussion of labora-
tory differences between patient groups can be found in the
supplemental material.
Focusing on the proteomic analysis, we found 56 protein
features to be differentially regulated between platelets from
STEMI and SCAD patients. The fact that those spots were
related to 42 unique genes suggests some cases of extensive
posttranslational modifications, quite common in platelets
Table 2. Selection of Proteins Involved in Platelet Signaling
Differentially Regulated in ST-Elevation Myocardial Infarction vs
Stable Coronary Artery Disease Patients
Protein Uniprot Code Spot
Fold
Change
14-3-3 protein / 1433Z_HUMAN 242 1.80*
-Actinin-1 ACTN1_HUMAN 2222 2.93*
ACTN1_HUMAN 2224 2.58*
ACTN1_HUMAN 2311 2.32*
Cdc42 CDC42_HUMAN 2006 1.82*
CrkL CRKL_HUMAN 1642 1.63
GADS GRAP2_HUMAN 2005 1.79
Inositol monophosphatase 1 IMPA1_HUMAN 717 1.61
Myosin-9 MYH9_HUMAN 1623 1.69*
MYH9_HUMAN 1918 1.98*
MYH9_HUMAN 2313 2.69*
Src SRC_HUMAN 1835 1.83
SKAP-HOM SKAP2_HUMAN 279 1.51*









SHP-1 PTN6_HUMAN 1723 1.61
A negative fold change indicates that the protein feature is downregulated in
ST-elevation myocardial infarction, whereas a positive fold change indicates
that the spot is upregulated in the acute group. SKAP-HOM indicates SKAP-55
homologue.
*Differentially regulated features have a P value of 0.05 except those
marked with an asterisk (*), which have a P value of 0.01.
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following activation, such as phosphorylations or natural
proteolysis. The latter also explains some cases where pro-
teins had an experimental molecular weight significantly
lower than the theoretical one. The number of differences was
higher than in the NSTE-ACS study we recently carried
out—40 protein spots related to 22 unique genes—which is
not surprising because the acute event was more severe in the
case of STEMI, and blood samples were collected closer to
the initiation of the event. That would be also one of the
explanations for why there was not a bigger overlap between
both studies. Nevertheless, there are similarities, and thus,
signaling and cytoskeletal proteins were the main functional
groups of proteins identified in both studies, with an impor-
tant number of differentially regulated proteins involved in
integrin and GPVI signaling. Moreover, Ingenuity Pathways
Analysis software revealed that most proteins identified in
both NSTE-ACS and STEMI studies are involved in a
network related to cell morphology.
Signaling Pathways as Possible Future Targets for
Antiplatelet Therapy: Upregulation of GPVI
Signaling in STEMI
In the past few years, studies identifying platelet receptors
and signaling mechanisms have yielded a trove of new targets
for antiplatelet therapy.2,11 For example, recent studies have
shown that several cell-surface receptor-ligand interactions
occur on close contact between platelets, such as the binding
of the ligand semaphorin 4D to its receptors, CD72 and plexin
B1. These receptors mediate platelet-platelet interactions and
thrombus retraction and hence are attractive therapeutic
targets.18 Proteomics has contributed to depicting the main
signaling pathways in platelets, leading to the identification
of novel receptors and signaling proteins, some of them
potential antithrombotic targets. We have been among the
pioneers in the field.10,13,19,20 In this way, the complexity of
outside-in and inside-out signaling has begun to be unraveled.
However, redundancy in signaling pathways makes it diffi-
cult to identify clear therapeutic targets. Nevertheless, there
are some exceptions. For instance, the binding of the cyto-
skeletal protein talin-1 to the cytoplasmic domain of 3-
integrin was shown to be required for activation of the IIb3
integrin.21 Moreover, changing a single amino acid in the
cytoplasmic domain of 3-integrin selectively disrupted
talin-1 binding and reduced arterial thrombosis in an animal
model22 showing that blockade of this interaction could be a
new antithrombotic strategy. Interestingly, most of the pro-
teins identified in the present study are interconnected in a
common network that primarily involves cytoskeletal and
signaling proteins, processes closely related to platelet acti-
vation. Indeed, integrin and GPVI signaling are among those
pathways highlighted by our study. Src family kinases play a
major role in these signaling cascades, especially in the case
of the collagen receptors GPVI and 21 and the fibrinogen
receptor IIb3.11 Interestingly, we demonstrate the active
form of Src is upregulated in STEMI patients, which suggests
a primary role for those pathways—where Src family kinases
are essential—in the acute event.
The integrin IIb3, mainly responsible for platelet aggre-
gation, is a well-known antiplatelet target.23 Integrin 21
Figure 4. GPVI signaling is upregulated in platelets from
ST-segment elevation myocardial infarction (STEMI) patients.
A, Western blot analysis of pTyr (4G10 monoclonal antibody),
Src-pTyr418, and GAPDH protein expression levels in basal
and collagen-related peptide (CRP)-activated platelets from
STEMI patients (n6) and stable coronary artery disease
(SCAD) (n6) and healthy (n6) controls. Equal amounts of
protein corresponding to each of the 6 patients per group
were pooled for each study point and loaded in different
lanes in a 4% to 12% NuPAGE Bis-Tris gel for protein sepa-
ration before Western blotting. B, Densitometry graph repre-
senting the values of band intensities corresponding to Src-
pTyr418 expression assessed by Western blot, with respect
to GAPDH. This analysis corresponds to the blot images
shown in A. IB indicates immunoblot.




 http://ahajournals.org by on January 22, 2021
was the first platelet collagen receptor to be identified and
serves as an adhesion receptor,11 so its involvement in the
acute activation of platelets makes sense in a collagen-rich
environment. The novelty of our study is to highlight other 3
platelet signaling pathways related to platelet activation in
ACS: actin cytoskeleton signaling, integrin-linked kinase
signaling, and GPVI signaling. The latter is an interesting
target. It has been recently shown that platelet GPVI binds to
collagenous structures in the core region of human atheroma-
tous plaque and is critical for atheroprogression in vivo.24
Indeed, inhibition of GPVI both via GPVI-Fc and anti-GPVI
antibodies resulted in protection against atherosclerosis in
rabbit and mice models.25 However, at present there are no
drugs in clinical use that block the binding of platelets to
collagen and von Willebrand factor and hence their adhesion
to the blood vessel wall. Our results reinforce the idea that
GPVI signaling, together with integrin and integrin-linked
kinase signaling, may be a good antiplatelet target for ACSs.
For example, in addition to the Src results, we found CrkL to
be upregulated in patients with STEMI. This adapter protein
has been shown to be involved in GPVI signaling.12 CrkL
consists of Src homology 2 and Src homology 3 protein-
binding domains and mediates assembly of protein com-
plexes in signaling.26 More precisely, it is an adapter for Syk,
a tyrosine kinase critical for collagen induced-platelet activa-
tion through GPVI.27 This association, demonstrated in vivo
and in vitro, could provide an explanation for the transloca-
tion of Syk to the cytoskeleton during platelet aggregation.27
As was the case with the active form of Src, the upregulation
of CrkL in patients with STEMI could be indicative of an
upregulation of pathways where this protein has been re-
ported to play a role, such as the GPVI signaling cascade. We
confirmed the latter by a specific GPVI signaling study on an
independent cohort of patients. As shown in Figure 4, there
was an upregulation of GPVI signaling in STEMI patients.
These results confirm our initial data and are also consistent
with recent reports that demonstrate that GPVI surface
expression is elevated in platelets from ACS patients.28,29
Conclusions
This study provides novel information on platelet proteome
changes related to STEMI and, in combination with our
recent study of platelets from NSTE-ACS patients, allows
highlighting of those signaling pathways more implicated in
the unwanted platelet activation associated with the acute
event: actin cytoskeleton signaling, integrin signaling,
integrin-linked kinase signaling, and GPVI signaling. In line
with the above, the adapter protein CrkL—known to partic-
ipate in GPVI signaling—and the active form of the tyrosine
kinase Src were found to be upregulated in platelets from
STEMI patients. Moreover, we show for the first time an
upregulation of GPVI signaling in STEMI patients. We hope
that our study will pave the way for future research on novel
therapeutic targets and platelet-related biomarkers in ACS.
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